<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-00497268</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-16T00:29:34+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="it">Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines</title>
            <author role="aut">
              <persName>
                <forename type="first">Silvia</forename>
                <surname>La Monica</surname>
              </persName>
              <idno type="halauthorid">471465-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Maricla</forename>
                <surname>Galetti</surname>
              </persName>
              <idno type="halauthorid">473928-0</idno>
            </author>
            <author role="crp">
              <persName>
                <forename type="first">Roberta R.</forename>
                <surname>Alfieri</surname>
              </persName>
              <email type="md5">364307e33d913a6e5242cd8f708c205f</email>
              <email type="domain">unipr.it</email>
              <idno type="idhal" notation="numeric">872861</idno>
              <idno type="halauthorid" notation="string">473929-872861</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Andrea</forename>
                <surname>Cavazzoni</surname>
              </persName>
              <idno type="halauthorid">473930-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Andrea</forename>
                <surname>Ardizzoni</surname>
              </persName>
              <idno type="halauthorid">473931-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Marcello</forename>
                <surname>Tiseo</surname>
              </persName>
              <idno type="halauthorid">473932-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Marzia</forename>
                <surname>Capelletti</surname>
              </persName>
              <idno type="halauthorid">473933-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Matteo</forename>
                <surname>Goldoni</surname>
              </persName>
              <idno type="halauthorid">473934-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Sara</forename>
                <surname>Tagliaferri</surname>
              </persName>
              <idno type="halauthorid">473935-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Antonio</forename>
                <surname>Mutti</surname>
              </persName>
              <idno type="halauthorid">473936-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Claudia</forename>
                <surname>Fumarola</surname>
              </persName>
              <idno type="halauthorid">473937-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Mara</forename>
                <surname>Bonelli</surname>
              </persName>
              <idno type="halauthorid">473938-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Daniele</forename>
                <surname>Generali</surname>
              </persName>
              <idno type="halauthorid">473939-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Pier Giorgio</forename>
                <surname>Petronini</surname>
              </persName>
              <idno type="halauthorid">473940-0</idno>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Hal</forename>
                <surname>Peer</surname>
              </persName>
              <email type="md5">8d58fc1b670b8074dd83e4a4c93d5914</email>
              <email type="domain">inria.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2010-07-03 02:50:33</date>
              <date type="whenWritten">2009-03-04</date>
              <date type="whenModified">2020-10-23 16:47:08</date>
              <date type="whenReleased">2010-07-03 02:50:33</date>
              <date type="whenProduced">2009-07-03</date>
              <date type="whenEndEmbargoed">2010-07-03</date>
              <ref type="file" target="https://hal.science/hal-00497268v1/document">
                <date notBefore="2010-07-03"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://hal.science/hal-00497268v1/file/PEER_stage2_10.1016%252Fj.bcp.2009.04.033.pdf" id="file-497268-692894">
                <date notBefore="2010-07-03"/>
              </ref>
              <ref type="externalLink" target="https://hal.archives-ouvertes.fr/hal-00497268/document"/>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="148147">
                <persName>
                  <forename>Hal</forename>
                  <surname>Peer</surname>
                </persName>
                <email type="md5">8d58fc1b670b8074dd83e4a4c93d5914</email>
                <email type="domain">inria.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-00497268</idno>
            <idno type="halUri">https://hal.science/hal-00497268</idno>
            <idno type="halBibtex">lamonica:hal-00497268</idno>
            <idno type="halRefHtml">&lt;i&gt;Biochemical Pharmacology&lt;/i&gt;, 2009, 78 (5), pp.460. &lt;a target="_blank" href="https://dx.doi.org/10.1016/j.bcp.2009.04.033"&gt;&amp;#x27E8;10.1016/j.bcp.2009.04.033&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Biochemical Pharmacology, 2009, 78 (5), pp.460. &amp;#x27E8;10.1016/j.bcp.2009.04.033&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-497268-692894"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="PEER">PEER Publishing and the Ecology of European Research</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="it">Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Silvia</forename>
                    <surname>La Monica</surname>
                  </persName>
                  <idno type="halauthorid">471465-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Maricla</forename>
                    <surname>Galetti</surname>
                  </persName>
                  <idno type="halauthorid">473928-0</idno>
                </author>
                <author role="crp">
                  <persName>
                    <forename type="first">Roberta R.</forename>
                    <surname>Alfieri</surname>
                  </persName>
                  <email type="md5">364307e33d913a6e5242cd8f708c205f</email>
                  <email type="domain">unipr.it</email>
                  <idno type="idhal" notation="numeric">872861</idno>
                  <idno type="halauthorid" notation="string">473929-872861</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Andrea</forename>
                    <surname>Cavazzoni</surname>
                  </persName>
                  <idno type="halauthorid">473930-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Andrea</forename>
                    <surname>Ardizzoni</surname>
                  </persName>
                  <idno type="halauthorid">473931-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Marcello</forename>
                    <surname>Tiseo</surname>
                  </persName>
                  <idno type="halauthorid">473932-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Marzia</forename>
                    <surname>Capelletti</surname>
                  </persName>
                  <idno type="halauthorid">473933-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Matteo</forename>
                    <surname>Goldoni</surname>
                  </persName>
                  <idno type="halauthorid">473934-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Sara</forename>
                    <surname>Tagliaferri</surname>
                  </persName>
                  <idno type="halauthorid">473935-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Antonio</forename>
                    <surname>Mutti</surname>
                  </persName>
                  <idno type="halauthorid">473936-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Claudia</forename>
                    <surname>Fumarola</surname>
                  </persName>
                  <idno type="halauthorid">473937-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Mara</forename>
                    <surname>Bonelli</surname>
                  </persName>
                  <idno type="halauthorid">473938-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Daniele</forename>
                    <surname>Generali</surname>
                  </persName>
                  <idno type="halauthorid">473939-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Pier Giorgio</forename>
                    <surname>Petronini</surname>
                  </persName>
                  <idno type="halauthorid">473940-0</idno>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">11103</idno>
                <idno type="issn">0006-2952</idno>
                <idno type="eissn">1873-2968</idno>
                <title level="j">Biochemical Pharmacology</title>
                <imprint>
                  <publisher>Elsevier</publisher>
                  <biblScope unit="volume">78</biblScope>
                  <biblScope unit="issue">5</biblScope>
                  <biblScope unit="pp">460</biblScope>
                  <date type="datePub">2009-07-03</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1016/j.bcp.2009.04.033</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="ro">Lung cancer</term>
                <term xml:lang="ro">EGFR</term>
                <term xml:lang="ro">Gefitinib</term>
                <term xml:lang="ro">Everolimus</term>
              </keywords>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>The epidermal growth factor receptor (EGFR) is a validated target for therapy in non-small cell lung cancer (NSCLC). Most patients, however, either do not benefit or develop resistance to specific inhibitors of the EGFR tyrosine kinase activity, such as gefitinib or erlotinib. The mammalian target of rapamycin (mTOR) is a key intracellular kinase integrating proliferation and survival pathways and has been associated with resistance to EGFR tyrosine kinase inhibitors. In this study, we assessed the effects of combining the mTOR inhibitor everolimus (RAD001) with gefitinib on a panel of NSCLC cell lines characterized by gefitinib-resistance and able to maintain pS6K phosphorylation after gefitinib treatment.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
  </text>
</TEI>